VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning

COPD Clinical Trial

Official title:

VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02224352
• Other study ID #: NSF-1417104
• Status: Recruiting
• Phase: N/A
• Start date: July 2014
• Est. completion date: March 2022

Study information

• Verified date: August 2021
• Source: Edward Hines Jr. VA Hospital
• Contact: Franco Laghi, MD
• Phone: 708/202-2705
• Email: Franco.Laghi[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Over one million patients in the US are estimated to undergo mechanical ventilation every year, and approximately 300,000 of them fail attempts at weaning. The morbidity and mortality of these patients is greater than in patients who are successfully weaned. It follows that treatments aimed at reducing the duration of mechanical ventilation have the potential to benefit society both in terms of human suffering and cost. Patients who fail attempts at weaning assist their inspiratory muscles during inhalation by recruiting their expiratory muscles during exhalation. Unfortunately, this recruitment occurs relatively late during a weaning trial. The knowledge that (a) expiratory muscle recruitment can assist inspiration, (b) the recruitment of the expiratory muscles is delayed during weaning, and (c) that the respiratory muscles in patients requiring mechanical ventilation are in a catabolic state raises the possibility that strategies designed to produce an early recruitment, and improve the strength, of the expiratory muscles could improve weaning outcomes in difficult to wean patients. The current investigation, which will be conducted in healthy subjects and in ambulatory patients with chronic obstructive pulmonary disease (COPD) at Edward Hines Jr. VAH (Aims 1 and 2), and in patients who are difficult to wean from mechanical ventilation at RML Specialty Hospital, Hinsdale, IL (Aim 3), has been designed to develop and assess a novel triggering algorithm (VentFree), that controls the delivery of non-invasive neuro muscular electrical stimulation (NMES) to the abdominal-wall muscles during exhalation, and to study the physiological (respiratory) responses to such stimulation in assisting respiration in healthy subjects, in ambulatory patients with COPD and in patients requiring pronged mechanical ventilation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: March 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Aim 1 and Aim 2:Healthy Subjects and Ambulatory COPD Patients Studied at Hines VAH

Healthy subjects (Hines VAH), Inclusion criteria:

• Age = 18 years
• No history of acute or chronic respiratory disease, cardiac or neuromuscular disease.

Ambulatory COPD patients (Hines VAH), Inclusion criteria:

• Age = 18 years
• Chronic airway obstruction defined as forced expiratory volume in one second (FEV1) of 70% predicted or less, ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) of 0.7 or less
• Stable clinical condition without an exacerbation during the preceding four weeks Aim 3: Patients being weaned from prolonged mechanical ventilation (RML Specialty

Hospital), Inclusion criteria:

• Age = 18 years
• History of neuromuscular disease
• Body mass index > 35 kg/m2
• Patients who have received mechanical ventilation for at least 14 days and the primary physician judges the patient is ready to start weaning
• Able to breathe spontaneously for more than 5 minutes and less than 12 hours
• Clinically stable: oxygen saturation > 90% with a fractional inspired oxygen = 0.40, external PEEP = 5 cm H2O, temperature ranging from 35.5 to 38.5Co, no intravenous administration of vasoactive agents. Additional inclusion/exclusion criteria for all potential participants
• Subjects with implanted electronic devices - such as cardiac pacemakers, defibrillators and intrathecal pumps - will be excluded because NMES could cause malfunction of those devices.
• Only subjects with intact abdominal-wall skin will be enrolled because NMES can cause discomfort when applied over skin that is irritated or on open wounds.
• Pregnancy will be a contraindication to participate in the study because it is unknown whether the application of NMES to the abdominal or lumbar area during pregnancy may produce adverse effects.
• Unable to comprehend and interact in English.

Related Conditions & MeSH terms

• COPD
• Weaning Failure

Intervention

Device:
• Functional neuromuscular electrical stimulation

Locations

Country	Name	City	State
United States	Edward G. Hines Jr., VA Hospital	Hines	Illinois
United States	RML Specialty Hospital	Hinsdale	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Edward Hines Jr. VA Hospital	RML Specialty Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity	Number of breaths that are correctly stimulated during exhalation over the total number of breaths taken.	10 minutes of resting breathing
Primary	Error rate	Number of false positive stimulation triggers over the total number of breaths taken.	10 minutes of resting breathing
Secondary	Tidal volume		10 minutes of resting breathing
Secondary	Respiratory rate		10 minutes of resting breathing
Secondary	Minute ventilation		10 minutes of resting breathing
Secondary	Esophageal pressure time product		10 minutes of resting breathing
Secondary	Trans diaphragmatic pressure time product		10 minutes of resting breathing
Secondary	Tension time index of the diaphragm		10 minutes of resting breathing
Secondary	Ratio of tidal change in Pga to tidal change in Pes		10 minutes of resting breathing